{"id":3669,"date":"2026-10-08T09:00:00","date_gmt":"2026-10-08T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3669"},"modified":"2026-10-08T19:55:26","modified_gmt":"2026-10-08T23:55:26","slug":"cln-049-enters-a-potentially-registrational-aml-study","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3669","title":{"rendered":"CLN-049 Enters a Potentially Registrational AML Study"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Cullinan Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

First patient dosed in potentially registrational Phase 2<\/p>\n

Modality<\/strong><\/p>\n

Bispecific T-cell engager (FLT3 x CD3)<\/p>\n

Asset<\/strong><\/p>\n

CLN-049<\/p>\n

Target<\/strong><\/p>\n

FLT3 (wild-type and mutant) and CD3 epsilon<\/p>\n

Disease Area<\/strong><\/p>\n

Relapsed or refractory acute myeloid leukemia; newly diagnosed TP53-mutated AML (exploratory)<\/p>\n

Summary<\/h4>\n

Cullinan dosed the first participant in a planned potentially registrational Phase 2 study of CLN-049 in relapsed or refractory acute myeloid leukemia. The study uses a brief two-dose optimization phase followed by seamless transition to a single-arm expansion at the selected dose and includes an exploratory newly diagnosed TP53-mutated AML cohort.<\/p>\n

The milestone is strategically important because it moves a broadly FLT3-directed T-cell engager toward registration without restricting eligibility to FLT3-mutant disease. It is not a clinical readout. The design concentrates evidentiary risk in response durability, marrow safety, infection burden, and the interpretability of a single-arm population after up to two prior lines.<\/p>\n

CLN-049 binds both FLT3 on leukemia cells and CD3 epsilon on T cells. Cullinan states that the molecule recognizes wild-type and mutant FLT3. The Phase 2 study enrolls patients with relapsed or refractory AML after no more than two prior lines, assesses two target dose levels, and then expands at the recommended Phase 2 dose without a concurrent control arm. The company expects a Phase 1 dose-escalation update in December 2026.<\/p>\n

A separate Phase 1\/2 study is beginning in newly diagnosed AML with CLN-049 plus azacitidine and venetoclax. CLN-049 has U.S. Fast Track and Orphan Drug designations for relapsed or refractory AML. The ongoing monotherapy record is NCT05143996, and the combination record is NCT07722767.<\/p>\n

Deep Analysis<\/h4>\n

FLT3 is attractive because it is expressed on many AML blasts and leukemia stem or progenitor compartments, and targeting wild-type FLT3 could broaden access beyond patients with FLT3 mutations. The same biology creates the central safety constraint: FLT3 is present on normal hematopoietic progenitors. A potent T-cell engager must therefore establish a therapeutic window between blast killing and prolonged marrow aplasia. Cytokine release, immune-effector-cell neurotoxicity, infection, cytopenia duration, and the capacity for count recovery are as important as response rate.<\/p>\n

A single-arm registrational path can be credible in refractory AML when effect size, depth, and durability clearly exceed historical outcomes in a well-defined population. Here, interpretability will depend on prior venetoclax exposure, prior FLT3 inhibition, transplant history, cytogenetic and molecular risk, baseline blast burden, and the proportion of patients able to proceed to transplant. Composite complete remission measures can look favorable without establishing durable survival or functional marrow recovery.<\/p>\n

The exploratory TP53-mutated cohort is biologically and clinically ambitious. TP53-mutated AML is frequently genomically complex, treatment resistant, and associated with rapid clonal evolution. T-cell redirection could bypass some intracellular resistance mechanisms, but antigen density, immunosuppressive marrow conditions, T-cell fitness in older patients, and myeloid progenitor toxicity remain limiting. A signal in this cohort would be meaningful only if supported by molecular clearance and durable remissions, not short-lived blast reduction.<\/p>\n

The combination with azacitidine and venetoclax creates both opportunity and confounding. Cytoreduction may improve engager tolerability and antigen accessibility, while overlapping cytopenias and infections may narrow the therapeutic window. Dose sequencing, step-up dosing, hospitalization requirements, and manufacturing simplicity will determine whether the approach can displace established salvage regimens or remain a bridge-to-transplant option.<\/p>\n

Company and Product Background<\/h4>\n

AML is an aggressive myeloid malignancy characterized by expansion of immature blasts and failure of normal hematopoiesis. Relapsed and refractory disease has poor outcomes, particularly after venetoclax-based therapy and in TP53-mutated disease.<\/p>\n

CLN-049 is an intravenously administered bispecific T-cell engager. By linking FLT3-positive cells to CD3-positive T cells, it is intended to trigger cytotoxic synapse formation and leukemia-cell killing. Unlike mutation-selective FLT3 kinase inhibitors, the molecule is designed to recognize both mutant and non-mutant FLT3.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified facts: the first Phase 2 participant has been dosed; the design includes two target doses, seamless single-arm expansion, and an exploratory TP53-mutated cohort; a December Phase 1 update is planned.<\/li>\n
  • Company claim: the FDA meeting supports a potentially registrational pathway. This describes a development plan, not regulatory agreement that efficacy evidence will be sufficient for approval.<\/li>\n
  • Interpretation A: broad FLT3 recognition can create a differentiated AML immunotherapy independent of mutation status. Support includes target prevalence and a pathway into pivotal testing. Contradiction: normal progenitor expression may cap exposure before durable disease control is reached.<\/li>\n
  • Interpretation B: the registrational framing is premature until mature Phase 1 data establish response depth, durability, and marrow recovery. Support is the absence of same-day efficacy data and the single-arm design. Contradiction would be a large, consistent effect across molecular subgroups with manageable step-up dosing and rapid count recovery.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a high-value hematology development signal, not evidence of efficacy. Cullinan has converted early regulatory dialogue into a faster path, but the asset\u2019s competitive position will be determined by the marrow-safety window and by whether responses persist beyond the period of T-cell activation.<\/p>\n

    The December Phase 1 update is the immediate falsification point. Upgrade evidence includes deep composite remissions, measurable residual disease clearance, manageable cytokine release, recovery of neutrophils and platelets, and durable bridging to transplant. Downgrade evidence includes prolonged aplasia, severe infection, early relapse through FLT3-low escape, or responses confined to a narrow dose or biomarker subgroup.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: neutral to cautiously positive. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Cullinan dosed the first participant in a planned potentially registrational Phase 2 study of CLN-049 in relapsed or refractory acute myeloid leukemia. The study uses a brief two-dose optimization phase followed by seamless transition…<\/p>\n","protected":false},"author":1,"featured_media":3677,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[76,993,754,994,995,525],"class_list":["post-3669","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-acute-myeloid-leukemia","tag-cln-049","tag-cullinan-therapeutics","tag-flt3","tag-t-cell-engager","tag-tp53-mutated-aml"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3669"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3669\/revisions"}],"predecessor-version":[{"id":3680,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3669\/revisions\/3680"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3677"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}